The DEA Just Argued Against Itself
Plus Virginia finally legalizes sales, a study that nearly erased opioids, and Pennsylvania's vote that leadership won't allow
Something fundamental has changed, and this week made it impossible to miss: cannabis is no longer outside the system asking to be let in. It’s inside the system, forcing every institution to clarify where it stands.
Look at the spread of fights this week. A state Senate is being pressured to simply allow a vote. The DEA and FDA stood up in a federal hearing and admitted cannabis is safer than alcohol and opioids — reversing decades of their own messaging. A study found cannabis nearly eliminated opioid use in chronic pain patients. The Supreme Court’s gun ruling is already rippling into other cases. And Virginia finally — finally — legalized actual sales.
This is the institutional phase. It’s harder to follow than the legalization era, and far more consequential. Here’s what happened, and what I actually think it means.
Pennsylvania’s fight isn’t about support anymore. It’s about whether leadership will allow democracy to function.
Every Democratic senator in Pennsylvania is backing a discharge resolution to force a bipartisan legalization bill out of committee and onto the floor. The bill has bipartisan sponsorship, the governor’s support, and 75% public approval — and it’s still stuck.
That’s the part worth sitting with. This isn’t a question of whether cannabis has support in Pennsylvania. It obviously does. It’s a question of whether Senate leadership will let the chamber vote on something most of the state already wants.
My read: Pennsylvania has stopped deciding whether cannabis should exist and started deciding whether it wants to regulate and tax a market that already exists all around it. Every day the bill sits in committee, Pennsylvania consumers drive across the border and hand their money — and the tax revenue attached to it — to New Jersey, Maryland, and New York. That’s not a moral stance against cannabis. It’s just leaving money on the table while pretending the market isn’t there. The procedural blockade is the whole story now.
The bottom line: Pennsylvania’s cannabis fight is no longer about public opinion. It’s about whether Senate leadership will let democracy move.
The opioid-displacement study is the most important medical cannabis data in a while.
Researchers studied 241 patients with treatment-resistant lower back pain and found inhaled cannabis produced large, sustained improvements — and near-total displacement of opioids, NSAIDs, antidepressants, and gabapentinoids.
I want to be careful not to overstate this — it’s one study, and cannabis isn’t a universal cure. But the finding matters enormously, and here’s why: lower back pain is one of the most common, costly, and opioid-entangled conditions in the world. Any intervention that reliably reduces opioid reliance in this population isn’t a wellness story. It’s a public-health story.
My read: this is where the medical cannabis conversation is finally maturing. For years the industry talked about THC percentage like it was the only variable that mattered. This study focused on delivery method — inhaled, for rapid onset and easier dose control — because that’s what actually drives patient outcomes. The sophisticated future of medical cannabis is in formulation, onset, consistency, and real-world results, not potency bragging rights. And the opioid angle reframes the entire policy debate: if cannabis can pull chronic-pain patients off opioids, medical access stops being a lifestyle question and becomes part of the overdose-crisis response.
The bottom line: Medical cannabis is increasingly judged by outcomes, not ideology — and the opioid-displacement data is getting very hard to dismiss.
The DEA and FDA just dismantled their own decades-old argument — on the record.
The rescheduling hearing opened with DEA and FDA officials highlighting cannabis’s medical benefits and its relative safety compared to alcohol and opioids, with the government acting as the formal proponent of moving cannabis to Schedule III.
Stop and appreciate how remarkable this is. Schedule I status rested entirely on two claims: no accepted medical use, and high abuse potential. This week, federal officials stood in an official proceeding and began building a record that says the opposite — that cannabis has medical value and comparatively lower harms.
My read: this is the single clearest signal yet that the old federal narrative is collapsing under its own weight. You cannot spend decades arguing cannabis has “no accepted medical use” and then have your own agencies testify to its medical benefits without fundamentally undermining the original position. That contradiction doesn’t just affect rescheduling — it weakens the government’s footing in every other cannabis fight, from the gun-rights cases to 280E.
But hold the celebration. The DEA still invited only reform opponents as formal participants, and still refuses to livestream. So we have a genuinely historic record being built inside a process designed to look one-sided. Both things are true at once.
The bottom line: The government is no longer defending the Schedule I narrative with any confidence. That’s historic — even inside a flawed process.
Idaho proves you can win the public and still lose to the process.
Idaho’s medical cannabis ballot campaign collected a large pile of signatures — and then hit the procedural wall. One county tossed roughly 4,000 signatures as late, and the campaign now faces uncertainty over residency verification and Idaho’s brutal district-level distribution requirement: 6% of registered voters in at least 18 of 35 legislative districts.
That district rule is the killer, and it deserves attention. A campaign can gather a massive raw signature total and still fail if those signatures aren’t spread correctly across the map.
My read: this is the under-discussed reality of cannabis reform in prohibitionist states. We talk about reform like it’s a persuasion problem — convince enough people and you win. But in states like Idaho, it’s an election-law problem: deadlines, county verification, paid circulators, distribution thresholds, and litigation. Ballot initiatives are often the only realistic path to reform in conservative states, and those paths are being deliberately narrowed by procedural barriers. Public momentum is necessary but nowhere near sufficient.
The bottom line: Idaho shows cannabis reform can have real public support and still get blocked by process. In prohibitionist states, the rules of the game matter as much as the votes.
Virginia finally ended its contradiction — and immediately created a new one.
Virginia did it. Lawmakers approved a budget package legalizing recreational sales, ending the bizarre limbo where adults could possess and grow cannabis since 2021 but had nowhere legal to buy it. Sales begin July 1, 2027 — up to two ounces per transaction, up to 350 licensed retailers, delivery allowed, and existing medical operators able to convert for a $10 million fee.
For the DMV region, this is a genuine shift — it reshapes the competitive map with Maryland and D.C., plus real estate, licensing, and tax dynamics across the region.
My read: this is a real victory, and I don’t want to undercut it. But the same bill raises the public-use fine from $25 to $250 — and as I covered last week, FOIA data shows public-use enforcement has already fallen disproportionately on Black Virginians since 2021. So Virginia resolved one contradiction (legal to possess, illegal to buy) and built another one (a legal market that preserves an enforcement tool with documented racial disparities). That $10 million conversion fee is also worth watching — it’s a number that quietly favors well-capitalized multi-state operators over smaller local players, which shapes who actually gets to participate in this market.
The bottom line: Virginia moved from limbo to legal commerce — but the fine structure and fee design will determine whether this market is actually fair.
The gun-rights ruling is already spreading — exactly as predicted.
The Supreme Court’s ruling protecting a cannabis consumer’s gun rights is already being applied to other cases, weakening the federal government’s blanket position that marijuana use automatically makes someone too dangerous to own a firearm.
I flagged this when the ruling first landed, and it’s playing out faster than expected. The key principle is individualized risk: the government can still regulate firearm possession by people who actually pose danger, but cannabis use alone is becoming a much weaker basis for automatic disqualification.
My read: this is cannabis doing what it keeps doing — exposing the federal government’s internal contradictions and forcing courts to resolve them. You can’t move toward recognizing cannabis’s medical value through rescheduling while simultaneously treating every medical cannabis patient as a categorically prohibited person. Courts have noticed, and now precedent is compounding. For patients specifically, this matters enormously: nobody using state-legal medicine should have to choose between symptom relief and a constitutional right. That forced choice is finally cracking.
The bottom line: Cannabis is colliding with constitutional law, and the broad federal assumptions about marijuana users are breaking down case by case.
The 280E tax fight exposes a genuine political contradiction.
A new op-ed targets Republican efforts to preserve punitive cannabis tax treatment under Section 280E — the rule barring businesses that traffic Schedule I or II substances from deducting ordinary expenses. If cannabis moves to Schedule III, 280E stops applying the same way, letting operators finally deduct rent, payroll, security, and marketing.
My read: I keep saying 280E matters more than most legalization headlines, and this is why. For many operators, the ability to deduct normal business expenses is literally the difference between survival and collapse. It distorts the entire market — compliant operators carry an effective tax rate that illicit sellers, who pay nothing, simply don’t.
The political contradiction the op-ed identifies is real and worth naming: some of the same lawmakers who campaign on lower taxes and supporting small business are working to preserve one of the harshest tax regimes imposed on any legal American industry. I try to keep this newsletter from being partisan, so I’ll put it neutrally — there’s a genuine tension between a stated philosophy of low taxes and pro-business policy, and an active effort to maintain 280E’s burden on legal operators. Readers can judge that tension for themselves. But operators should understand the stakes: rescheduling may be the single largest tax event in cannabis history.
The bottom line: Rescheduling isn’t just drug policy. It may be the biggest tax event the industry has ever seen — and there’s real political resistance to letting it happen.
The activists outside DEA headquarters are making the right argument.
Cannabis reform activists protested outside DEA headquarters over their exclusion from the rescheduling hearing — which features only legalization opponents as formal parties, with no livestream for the public.
I’ve covered the access problem the past two weeks, but the activists are sharpening the framing in a useful way: this isn’t only about the final rule. It’s about the record that gets built along the way.
My read: the procedural questions sound boring, and that’s exactly why they’re dangerous to ignore. Who testifies? Who cross-examines? Who counts as an “interested person”? Who gets excluded? Those technical choices shape the evidentiary record — and that record is what courts will lean on for years when the inevitable legal challenges come. The opposition understands that building the record is half the battle. The reform movement is, belatedly, realizing it too. Federal reform isn’t won by public-opinion polls or state legalization maps. It’s won through administrative law and procedural legitimacy — terrain the industry has historically underinvested in.
The bottom line: The rescheduling fight is now a fight over the record itself — and reformers are right not to let opponents define it alone.
Final thought
The cannabis industry has stopped waiting for one clean legalization moment to arrive. It isn’t coming.
Instead, the industry is being shaped by eight systems at once: state legislatures, courts, ballot campaigns, federal agencies, tax law, medical research, public opinion, and administrative hearings. All moving at different speeds, sometimes in opposite directions.
That makes this era genuinely harder to follow than the activist days. A single ballot-night victory is easy to understand. A discharge resolution, a 280E deduction fight, a signature-distribution requirement, and an administrative hearing record are not.
But that complexity is the whole point. This is what an industry looks like once it’s real — woven into every institution, forcing each one to take a position.
The next winners won’t just understand cannabis. They’ll understand government.
That’s what this newsletter is for.
What’s the biggest regulatory challenge your operation is facing right now? Hit reply — I read every response and it shapes what I cover next week.
If this was useful, forward it to someone in the cannabis space or hit the restack button on Substack. It’s how this community grows.